PLx Pharma (PLXP) and Its Competitors Head-To-Head Comparison

PLx Pharma (NASDAQ: PLXP) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare PLx Pharma to similar businesses based on the strength of its dividends, institutional ownership, risk, profitability, valuation, earnings and analyst recommendations.


This table compares PLx Pharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PLx Pharma N/A -154.79% -86.47%
PLx Pharma Competitors -5,318.18% -110.23% -37.45%

Volatility & Risk

PLx Pharma has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, PLx Pharma’s peers have a beta of 2.55, meaning that their average share price is 155% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for PLx Pharma and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PLx Pharma 0 0 2 0 3.00
PLx Pharma Competitors 1269 3671 12226 263 2.66

PLx Pharma currently has a consensus target price of $14.00, indicating a potential upside of 124.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.95%. Given PLx Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe PLx Pharma is more favorable than its peers.

Valuation & Earnings

This table compares PLx Pharma and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PLx Pharma N/A -$21.32 million N/A
PLx Pharma Competitors $275.31 million -$19.68 million 87.40

PLx Pharma’s peers have higher revenue and earnings than PLx Pharma.

Insider & Institutional Ownership

25.5% of PLx Pharma shares are held by institutional investors. Comparatively, 49.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 47.7% of PLx Pharma shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


PLx Pharma peers beat PLx Pharma on 7 of the 12 factors compared.

About PLx Pharma

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply